<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735332</url>
  </required_header>
  <id_info>
    <org_study_id>TLN-232-202</org_study_id>
    <nct_id>NCT00735332</nct_id>
  </id_info>
  <brief_title>Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma</brief_title>
  <official_title>A Phase IIa Study of TLN-232 as Second-line Therapy for Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thallion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thallion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of TLN-232 used to treat
      patients with metastatic melanoma that recur/progress after receiving first line systemic
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    License termination.
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of TLN-232 in patients with recurrent metastatic melanoma measured by overall response rate at 16 weeks from date of initial infusion of TLN-232 (Day 1, Cycle 1).</measure>
    <time_frame>Complete response, partial response or stable disease at 16 weeks from date of initial infusion of TLN-232 (Day 1, Cycle 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability of TLN-232 in patients with recurrent metastatic melanoma</measure>
    <time_frame>Maximum 13 months from date of initial infusion of TLN-232 (Day 1, Cycle 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLN-232</intervention_name>
    <description>21 day continuous IV administration of TLN-232 followed by a 7-day recovery period</description>
    <arm_group_label>Single-Arm</arm_group_label>
    <other_name>Formerly CAP-232</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed stage IV (M1a, M1b, and M1c) unresectable metastatic melanoma
             (cutaneous, mucosal or acral lentiginous)

          -  First progression after treatment by one first line systemic therapy for metastatic
             melanoma (immunotherapy or targeted therapy or chemotherapy or any combination of
             them)

          -  Measurable recurrent/progressive disease by radiological scan ≤ 21 days prior to Day
             1, Cycle 1

          -  Age ≥ 18 years

          -  ECOG ≤ 2

          -  Normal organ and marrow function as defined below:

               -  Leukocytes ≥2.5 x 109/L

               -  Absolute neutrophil count ≥1.5 x 109/L

               -  Platelets ≥100 x 109/L

               -  Hemoglobin ≥100 g/L (10g/dL)

               -  Total bilirubin ≤1.5 X institutional ULN

               -  AST(SGOT)/ALT(SGPT) ≤2.5 X institutional ULN

               -  Creatinine ≤1.5 X institutional ULN

        Exclusion Criteria:

          -  Patients with a life expectancy ≤ 16 weeks

          -  Patients with ocular melanoma

          -  Patients with symptomatic and/or unstable brain metastasis during the last 3 months
             (90 days) prior to Day 1, Cycle 1

          -  Patients with a history of allergic reactions or hypersensitivity to somatostatin
             analogues

          -  Patients with a documented history of HIV, active hepatitis B or C infection

          -  Female patients who are pregnant or lactating

          -  Patients who are receiving hormonal therapy (with the exception of hormone replacement
             therapy and hormonal contraceptives), systemic steroids, immunosuppressive therapy or
             coumadin (low molecular weight heparin is permitted)

          -  Patients with grade ≥2 peripheral neuropathy (CTCAE criteria)

          -  Patients in whom a proper central line cannot be established
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hogg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>August 4, 2010</last_update_submitted>
  <last_update_submitted_qc>August 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Didier Reymond, MD / Executive Vice-President Clinical Development</name_title>
    <organization>Thallion Pharmaceuticals Inc.</organization>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>Phase II</keyword>
  <keyword>Skin Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

